Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tapentadol PR randomized withdrawal trial in chronic malignant tumor-related pain
2007-001985-34Phase 3Terminated
- Sponsor
- & Johnson Pharmaceutical Research & Development, L.L.C.
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tapentadol in cancer pain and chronic pain (3 arms), sponsored by & Johnson Pharmaceutical Research & Development, L.L.C. Primary endpoint: Primary efficacy endpoint. Started Oct 2007; status: terminated.
02
Drugs
tapentadol
03
Conditions
cancer painchronic pain
Beyond the preview
Go deeper on 2007-001985-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001985-34.